Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$656.96M+208.52%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Parth Mehrotra
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 1,226
- Beta
- 0.77
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.64
Financials
Revenue
$656.96M+208.5%Net Income
$13.49M+149.1%EBITDA
$25.77M+277.1%Free Cash Flow
$28.94MEPS (diluted)
$0.10+89.8%Shares Outstanding (diluted)
132.71M+29.1%Operating Expenses
$44.39MCash & Debt
$446.28MRevenue by Segment (annual)
$2.12BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.12B | $22.92M | $0.19 |
| 2024 | $1.74B | $14.38M | $0.12 |
| 2023 | $1.66B | $23.08M | $0.20 |
| 2022 | $1.36B | $-8.59M | $-0.08 |
| 2021 | $966.22M | $-188.23M | $-1.77 |
| 2020 | $817.08M | $31.24M | $0.30 |
| 2019 | $786.36M | $8.24M | $0.08 |
| 2018 | $657.61M | $-3.04M | $-0.03 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.28
- Implied price
- $4.96
- Return from $24.69
- -27.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.47 — -90.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -39.3% | -36.5% | -34.2% | -32.1% | -30.3% |
| 3.0% | -36.2% | -33.3% | -30.8% | -28.6% | -26.7% |
| 8.0% | -33.1% | -30.1% | -27.5% | -25.2% | -23.2% |
| 13.0% | -30.0% | -26.8% | -24.1% | -21.7% | -19.6% |
| 18.0% | -26.9% | -23.6% | -20.7% | -18.3% | -16.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (12)
- Newszacks.com·3d ago·Neutral
Can Privia Health (PRVA) Run Higher on Rising Earnings Estimates? Privia Health (PRVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
… in Total Medicare Savings Company Increases Full-Year 2026 Financial Guidance a ARLINGTON, Va., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that its Accountable Care Organizations (ACOs) achieved shared savings of $374.0 million through the Medicare Shared Savings Program (MSSP) for the 2025 performance year, a 59.7% increase from 2024.
View source ↗ - Newszacks.com·12d ago·Neutral
3 Reasons Why Growth Investors Shouldn't Overlook Privia Health (PRVA) Privia Health (PRVA) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Privia Health Group Q3 Earnings Call Highlights Privia Health Group NASDAQ: PRVA raised its 2026 financial outlook after reporting growth in providers, patient attribution and adjusted earnings through the first nine months of the year. The company also announced a $36 million acquisition that will expand its Medicare value-based care footprint in 2027.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Privia Health Group, Inc. (PRVA) Q3 2026 Earnings Call Transcript Privia Health Group, Inc. (PRVA) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Positive
Privia Health (PRVA) Q3 Earnings and Revenues Top Estimates Privia Health (PRVA) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.05 per share a year ago.
View source ↗ - Newsglobenewswire.com·17d ago·Positive
Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results Privia Health Reports Strong Q3 and YTD 2026 Results - Adjusted EBITDA of $114.7M, +21.9% from YTD'25 – FY'26 Guidance Raised for All Key Financial Metrics
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Privia Health Expands VBC Footprint with Acquisition of American Choice Healthcare MSSP Business ARLINGTON, Va., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the acquisition of American Choice Healthcare MSSP, LLC (ACH), a wholly-owned subsidiary of Cano Health.
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Privia Health Group: Operating Leverage Could Lead To Share Price Upside Privia Health Group is rated BUY, supported by strong operating leverage and expanding value-based care, positioning for earnings upside. PRVA trades at a 48% discount to its five-year average forward EV/EBITDA, with 24% forward EBITDA growth, outpacing peers. 2Q26 results showed 15% care margin growth, 29% adjusted EBITDA growth, and robust provider and patient expansion, highlighting operating efficiency.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Privia Health to Report Third Quarter 2026 Results on Thursday, November 5 ARLINGTON, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, 2026 before market open on Thursday, November 5, 2026.
View source ↗ - Newsbusinesswire.com·48d ago·Neutral
Anthem Blue Cross and Blue Shield in Virginia and Privia Health Reach New Agreement RICHMOND, Va.--(BUSINESS WIRE)--Anthem Blue Cross and Blue Shield in Virginia and Privia Health have reached a new agreement that will continue providing Anthem members with in-network access to Privia Medical Group physicians across Virginia.The agreement reflects a shared commitment to ensuring Virginians have access to high-quality healthcare while advancing value-based care and helping keep healthcare afforda
View source ↗ - Newsglobenewswire.com·96d ago·Neutral
Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.11 per share
Typical surprise -16.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.21 vs $0.09beat
- Thu, Aug 6$0.07 vs $0.07beat
- Thu, May 7$0.02 vs $0.08miss
- Thu, Feb 26$0.07 vs $0.04beat
- Thu, Nov 6$0.05 vs $0.06miss
- Thu, Aug 7$0.02 vs $0.05miss
Estimates and results for PRVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRVA officers and directors.
- Bought
- —
- Sold
- $20.0m
0 trades
39 trades
- Mountcastle Davidsold
- Mountcastle Davidsold
- Morris Matthew Shawnsold
- Morris Matthew Shawnsold
- Mountcastle Davidsold
- Morris Matthew Shawnsold
- Morris Matthew Shawnsold
- Morris Matthew Shawnsold
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PRVA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
